Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.35
Bid: 1.30
Ask: 1.40
Change: 0.125 (10.20%)
Spread: 0.10 (7.692%)
Open: 1.225
High: 1.35
Low: 1.20
Prev. Close: 1.225
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Price Monitoring Extn

4 Aug 2021 16:41

RNS Number : 6116H
Shield Therapeutics PLC
04 August 2021
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APMDZGGRKDMGMZM

Date   Source Headline
4th Feb 20227:00 amRNSKOL Investor Event on Iron Deficiency
7th Jan 20227:00 amRNSInvestor Presentation
5th Jan 20227:00 amRNSLicence Agreement in Canada for Accrufer®
30th Dec 20219:06 amRNSSecond Price Monitoring Extn
30th Dec 20219:00 amRNSPrice Monitoring Extension
29th Dec 202111:05 amRNSSecond Price Monitoring Extn
29th Dec 202111:00 amRNSPrice Monitoring Extension
16th Dec 202111:05 amRNSSecond Price Monitoring Extn
16th Dec 202111:00 amRNSPrice Monitoring Extension
16th Dec 20217:00 amRNSPatient Access Expands for Accrufer®
7th Oct 20219:45 amEQSHardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research
30th Sep 20215:30 pmRNSBlock Listing 6 Monthly Return
27th Sep 20217:00 amRNSJose A. Menoyo Appointed as Chief Medical Officer
21st Sep 20217:00 amRNSInvestor presentation
23rd Aug 20217:00 amRNSPDMR Transaction Notification
20th Aug 202111:08 amEQSHardman & Co Research: Shield Therapeutics (STX) - Focused on US market penetration
17th Aug 20217:00 amRNSHalf-year Report
12th Aug 20217:25 amEQSHardman & Co Video Event | Shield Therapeutics plc - Investor Forum
12th Aug 20217:00 amRNSLicence agreement secured in Republic of Korea
11th Aug 20217:00 amRNSNotice of Results
9th Aug 20217:00 amRNSAEGIS-CKD study results published in AJKD
4th Aug 20214:41 pmRNSSecond Price Monitoring Extn
4th Aug 20214:35 pmRNSPrice Monitoring Extension
4th Aug 20212:05 pmRNSSecond Price Monitoring Extn
4th Aug 20212:00 pmRNSPrice Monitoring Extension
24th Jun 20217:00 amRNSUS launch of Accrufer® confirmed for July 1, 2021
23rd Jun 20214:40 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:35 pmRNSPrice Monitoring Extension
21st Jun 20211:35 pmRNSInvestor presentation
18th Jun 20217:00 amRNSDirectorate Change
17th Jun 20212:30 pmRNSResults of 2021 Annual General Meeting
15th Jun 20216:15 pmRNSGrant of share options to the CEO
28th May 20217:00 amRNSAppointment of new Chief Executive Officer
28th May 20217:00 amRNSTotal Voting Rights
26th May 202110:35 amEQSHardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule
21st May 20217:00 amRNSUS update
18th May 20217:00 amRNSAEGIS-H2H study results published in IBD
17th May 20217:00 amRNSCommencement of trading on the OTCQX Best Market
13th May 20213:00 pmRNS2020 Annual Report and 2021 AGM Notice
10th May 20217:00 amRNSAppointment of Two Non-Executive Directors
6th May 20211:44 pmRNSTotal Voting Rights Update
29th Apr 20217:00 amRNSPreliminary Results
22nd Apr 20217:00 amRNSNotice of Results
7th Apr 20219:33 amRNSHolding(s) in Company
7th Apr 20219:31 amRNSHolding(s) in Company
6th Apr 202111:05 amRNSSecond Price Monitoring Extn
6th Apr 202111:00 amRNSPrice Monitoring Extension
6th Apr 20217:00 amRNSHolding(s) in Company
31st Mar 20213:01 pmRNSTotal Voting Rights Update
31st Mar 20213:00 pmRNSBlock Listing 6 Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.